Biopharmaceutical News and Research

RSS

Quintiles' anatomic pathology services now available in China to help develop effective cancer treatments

Quintiles today announced the availability of anatomic pathology services through its central laboratory in Beijing, China, to help biopharmaceutical companies develop more effective cancer treatments. These services complement assay development, digital pathology and core lab offerings available through the facility to help customers comply with China’s restrictions on tissue import/export.

17 Feb 2010

Fourth-quarter and full-year 2009 results announced by Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2009.

16 Feb 2010

Meda publishes 2009 year-end report

“The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”

16 Feb 2010

Bioniche Life Sciences meets obligations under licensing agreement with Endo Pharmaceuticals

Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today announced that it has met the obligations associated with two milestones under its licensing agreement with Endo Pharmaceuticals for exclusive rights to develop and market Bioniche's proprietary product for non-muscle-invasive bladder cancer in North America.

15 Feb 2010

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia's latest clinical results follow two earlier successful phase II studies with the company's T-cell vaccine against cat allergy.

12 Feb 2010

NeoStem prices public offering of 5M common stock shares at $1.35 per share

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it priced a public offering of 5,000,000 shares of its common stock at $1.35 per share. Net proceeds from the offering, after underwriting discounts and commissions and expenses, will be approximately $5,697,500. NeoStem has granted the underwriters an option to purchase up to an additional 750,000 shares to cover over-allotments, if any.

12 Feb 2010

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.

12 Feb 2010

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.

12 Feb 2010

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a Phase I clinical trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).

11 Feb 2010

PAREXEL International, Proteome Sciences form biomarker alliance

PAREXEL International Corporation, a leading global biopharmaceutical services provider, and Proteome Sciences plc, a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of an alliance focused on enhancing PAREXEL's biomarker capabilities for early phase clinical development. PAREXEL is using Proteome Sciences' PS Biomarker Services™ protein and peptide biomarker capabilities to support biopharmaceutical companies in making earlier assessments of new compounds in development.

From Parexel 11 Feb 2010

Intellect Neurosciences: Several significant stakeholders commit funds

Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease ("AD"), announced today that several of its significant shareholders (the "Interested Shareholders") have agreed in principle to provide interim funding to the Company and assist the Company in its efforts to restructure its balance sheet.

11 Feb 2010

Indiana's pharmaceutical research and manufacturing companies maintained steady growth in 2009

Indiana's contract pharmaceutical research and manufacturing companies continued to expand in 2009, despite challenges in the biopharmaceutical contract service sector due to the downturn in the economy, the prospect of healthcare reform and other market developments.

11 Feb 2010

PLAN C Agency launches Hepatitis B awareness campaign in the West Coast

PLAN C Agency, in collaboration with biopharmaceutical company Gilead Sciences, launched a Hepatitis B awareness campaign titled "B HERE" at three college campuses in the West Coast. The goal was to raise the much needed awareness regarding the rising epidemic of Hepatitis B among Asian Americans and educate the youth on the importance of getting tested.

11 Feb 2010

MDS to divest remaining MDS Pharma Services Early Stage business for $45M

MDS Inc., a leading provider of products and services to the global life sciences markets, today announced that it has signed agreements to divest its remaining MDS Pharma Services Early Stage business, which provides Discovery through Phase IIa clinical trial services to biotechnology and pharmaceutical companies, for $45 million and certain minority equity interests.

10 Feb 2010

Avrio Biopharmaceuticals receives Cal FDB approval to manufacture and ship pharmaceutical products

Avrio Biopharmaceuticals, LLC, a wholly-owned subsidiary of Irvine Pharmaceutical Services, Inc., received approval to manufacture and ship pharmaceutical products by the California Department of Public Health, Food and Drug Branch (Cal FDB), completing the organization's portfolio of product development services in support of its pharmaceutical, biopharmaceutical, and medical device clients.

10 Feb 2010

Second-quarter fiscal 2010 results announced by Bioniche Life Sciences

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 second quarter, ended December 31, 2009.

10 Feb 2010

Provectus Pharmaceuticals publishes article on novel treatment for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces the publication of an article, entitled “A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series," authored by Dr. Matthew C. Foote, Dr. Bryan H. Burmeister, Janine Thomas, and Dr. B. Mark Smithers, in the current issue of the peer-reviewed journal, Melanoma Research (20(1):48-51, February 2010).

10 Feb 2010

Sartorius releases preliminary unaudited figures for fiscal 2009

Today Sartorius, a leading international process and laboratory technology provider, released its preliminary unaudited figures for fiscal 2009. In the reporting period, business in both Group divisions showed substantially divergent trajectories.

From Sartorius 10 Feb 2010

Thrombogenics announces publication of positive microplasmin Phase II trial results

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II trial results, evaluating the product's efficacy and safety in patients who require vitrectomy, have been published in the prestigious American Academy of Ophthalmology's Journal, Ophthalmology, the leading journal for the vitreoretinal community.

9 Feb 2010

Targacept receives grant for developing alpha6*-selective NNR Imaging Agent as Parkinson’s disease biomarker

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The grant is to fund a project entitled: “Development of an alpha6*-selective Neuronal Nicotinic Receptor (NNR) Imaging Agent as a Parkinson’s Disease Biomarker” and is the second awarded to Targacept by MJFF in the last six months.

9 Feb 2010

Biopharmaceutical News and Research

Quintiles' anatomic pathology services now available in China to help develop effective cancer treatments

Fourth-quarter and full-year 2009 results announced by Vanda Pharmaceuticals

Meda publishes 2009 year-end report

Bioniche Life Sciences meets obligations under licensing agreement with Endo Pharmaceuticals

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

NeoStem prices public offering of 5M common stock shares at $1.35 per share

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

PAREXEL International, Proteome Sciences form biomarker alliance

Intellect Neurosciences: Several significant stakeholders commit funds

Indiana's pharmaceutical research and manufacturing companies maintained steady growth in 2009

PLAN C Agency launches Hepatitis B awareness campaign in the West Coast

MDS to divest remaining MDS Pharma Services Early Stage business for $45M

Avrio Biopharmaceuticals receives Cal FDB approval to manufacture and ship pharmaceutical products

Second-quarter fiscal 2010 results announced by Bioniche Life Sciences

Provectus Pharmaceuticals publishes article on novel treatment for metastatic melanoma

Sartorius releases preliminary unaudited figures for fiscal 2009

Thrombogenics announces publication of positive microplasmin Phase II trial results

Targacept receives grant for developing alpha6*-selective NNR Imaging Agent as Parkinson’s disease biomarker

eBook: Using iPSCs models for human disease research and drug discovery eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News